Global Tetracyclines Market – Industry Trends and Forecast to 2029

Global Tetracyclines Market, By Drugs (Doxycycline, Demeclocycline, Minocycline, Others), Indication (Acne, Bronchiectasis, Gastroenteritis, Chlamydia Infection, Others),  Drug Type (Branded, Generics), Mode of Purchase (Prescription, Over-the-Counter), Dosage Form (Tablets, Capsules, Powder, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Market Analysis and Size                              

Tetracycline medicines are an antibacterial class of medications that work by inhibiting bacterial protein synthesis. These are made from Streptomyces bacteria of various strains. The pharmacological molecules bind to the 30S ribosomal subunit in an irreversible manner, inhibiting the bacterial protein elongation step. Tetracyclines can be found in both lyophilic and hydrophilic forms, allowing them to interact with both gram-positive and gram-negative bacteria. A few gram negative bacterial strains, such as Proteus mirabilis, have an inherent resistance to certain tetracyclines, rendering these medications useless against them, but no resistance has been detected in gram-positive strains.

Data Bridge Market Research analyses that the tetracyclines market was valued at USD 33.64 billion in 2021 and is expected to reach USD 40.99 billion by 2029, registering a CAGR of 2.50% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Tetracyclines are antibiotics that can be used to treat infections caused by susceptible microorganisms such as bacteria, chlamydiae, mycoplasmata, protozoans, or rickettsiae. Tetracyclines stop bacteria RNA from making proteins (an important molecule that acts as a messenger for DNA). They are primarily bacteriostatic, meaning they prevent bacteria from proliferating but do not kill them. Tetracycline is also used to treat Lyme disease and malaria, as well as to prevent plague and tularemia in patients who have been exposed to the microorganisms that cause the diseases.

Tetracyclines Market Dynamics

Drivers

• Increasing prevalence of infectious diseases

The increasing prevalence of infectious diseases across the globe will fuel industry growth. Tetracycline is used to treat bacterial infections such as pneumonia and other respiratory diseases. Plague and tuleramia (serious infections that may be spread on purpose as part of a bioterror attack) are also treated with tetracycline. It can also be used to treat certain types of food poisoning and anthrax in patients who cannot be treated with penicillin. It works by preventing bacteria from growing and spreading.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of tetracyclines market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Surging geriatric population

The surging geriatric population is estimated to enhance the market's growth rate during the forecast period of 2022-2029. The geriatric population is among the age group mostly impacted by infectious diseases. Due to their less sensitive immune system, they are more susceptible to infection. As a result, the world's expanding geriatric population is predicted to boost demand for antibiotics globally and boost the tetracyclines market's growth over the forecast period. According to the United Nations' World Population Ageing Highlight 2020 report, the global geriatric population is expected to grow from 727 million in 2020 to 1.5 billion by 2050, a nearly two-fold increase, as the share of the geriatric population in 2020 was about 9.3 percent, and is expected to rise to 16 percent by 2050.

Furthermore, rise in the number of government initiatives to spread awareness will result in the expansion of tetracyclines market. Along with this, the sedentary lifestyle of people and increasing level of disposable income will enhance the market's growth rate.

Opportunities

• Availability of a large number of generics     

The availability of a large number of generics lowers the cost of these treatments in emerging nations, increasing demand in these markets. Governments all across the globe have taken steps to encourage tetracycline drug discovery in order to address the critical need for better treatment of bacterial illnesses and to counteract the increasing spread of antibiotic-resistant microorganisms. Doxycycline, demeclocycline, chlortetracycline, meclocycline, clomocycline, lymecycline, minocycline, tetracycline, oxytetracycline, metacycline, penimepicycline, bedaquiline, tigecycline and rolitetracycline are some of the most common tetracycline generic medications on the market.

Moreover, the market's growth is fueled by rising technological advancement and emerging new markets. These factors will provide beneficial opportunities for the tetracyclines market growth. Also, the increase in the number of research and development activities will provide beneficial opportunities for the tetracyclines market's growth.

Restraints/Challenges

On the other hand, the high cost of drug development and distribution will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the tetracyclines market. Additionally, lack of awareness among people and side effects linked with tetracyclines such as Photosensitivity reactions. headache, acid reflux, pigmentation, diarrhea, itching, nausea, vomiting, and others will restrain and further impede the market's growth rate during the forecast period of 2022-2029.

This tetracyclines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tetracyclines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Tetracyclines market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Tetracyclines Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, impacting a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the tetracyclines market. On the bright side, the tetracyclines market will likely improve as respective government bodies have lifted the enforced lockdown restrictions. Various sectors are anticipated to rebound quickly post COVID-19 pandemic due to the wide number of applications they serve. As a result, the market is projected to stabilize in the future.

Global Tetracyclines Market Scope

The tetracyclines market is segmented on the basis of drugs, indication, mode of purchase, dosage form, drug type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Doxycycline
• Demeclocycline
• Minocycline
• Others

Indication

• Acne
• Bronchiectasis
• Gastroenteritis
• Chlamydia Infection
• Others

Mode of Purchase

• Prescription
• Over-the-Counter

Dosage Form

• Tablets
• Capsules
• Powder
• Others

Drug Type

• Branded
• Generics

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Pipeline Analysis

Omadacycline: New Tetracycline Antibiotic Effective in Community-Acquired Bacterial Pneumonia

Omadacycline is a once-daily tetracycline that has in vitro activity against various CAP pathogens, including Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, and atypical organisms such Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydia pneumoniae. In terms of early clinical response (81.1 percent vs. 82.7 percent, respectively) and posttreatment clinical response rates (87.6 percent vs. 85.1 percent), omadacycline was noninferior to moxifloxacin. In the treatment of selected patients with CAP, omadacycline has a similar therapeutic benefit to moxifloxacin.

Tetracyclines Market Regional Analysis/Insights

The tetracyclines market is analysed and market size insights and trends are provided by country, drugs, indication, mode of purchase, dosage form, drug type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the tetracyclines market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Asia-Pacific dominates the tetracyclines market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the rising number of generic drug manufacturers and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, the high prevalence of bacterial infections and rise in government initiatives and specialist communities will further propel the market's growth rate in this region.

North America is expected to grow significantly during the forecast period of 2022-2029 due to the presence of sophisticated medical facilities for optimizing the treatment in this region. Also, the development of healthcare infrastructure and high diagnostic rate will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Tetracyclines Market Share Analysis

The tetracyclines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to tetracyclines market.

Some of the major players operating in the tetracyclines market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Aurobindo Pharma (India)
• Cipla Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Takeda Pharmaceutical Company Limited (Japan)
• Almirall, S.A (Spain)
• Akorn, Incorporated (U.S.)
• Torrent Pharmaceuticals Ltd. (India)
• Amneal Pharmaceuticals LLC. (U.S.)
• Dr. Reddy's Laboratories Ltd. (India)
• Zydus Cadila (India)